Captirall
Description of the study :
Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence
Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence
Download the patient file :
Clinical trial parameters :
Skeleton = (0.05, 0.10, 0.20, 0.25)
A vector of initial guesses of toxicity probabilities associated the doses
Target = 0.2
The target DLT rate
Obswin = 28
The observation window with respect to which the MTD is defined
A vector of initial guesses of toxicity probabilities associated the doses
Target = 0.2
The target DLT rate
Obswin = 28
The observation window with respect to which the MTD is defined
Scale = √1.34
Standard deviation of the normal prior of the model parameter
Conf level = 0.95
Confidence level for the probability/confidence interval of the returned dose-toxicity curve
Standard deviation of the normal prior of the model parameter
Conf level = 0.95
Confidence level for the probability/confidence interval of the returned dose-toxicity curve
Dose assignment :
Data summary and toxicity probability update :
Download data file :
Click below to generate a PDF containing the data of the clinical trial: